NCT02455180View on ClinicalTrials.gov

Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Multiple Organ FailureSepsisSystemic Inflammatory Response SyndromeTrauma
Interventions
DRUG

Ascorbic Acid

Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.

Trial Locations (1)

1081 HV

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER

NCT02455180 - Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients | Biotech Hunter | Biotech Hunter